Please use this identifier to cite or link to this item:
http://ri.uaemex.mx/handle20.500.11799/109286
DC Field | Value | Language |
---|---|---|
dc.creator | José Meneses Calderón | - |
dc.creator | María del Rocío Figueroa Flores | - |
dc.creator | Leopoldo Paniagua Coria | - |
dc.creator | JESÚS CARLOS BRIONES GARDUÑO | - |
dc.creator | Jazmín Meneses Figueroa | - |
dc.creator | María José Vargas Contreras | - |
dc.creator | Lilia de la Cruz | - |
dc.creator | Salvador Díaz Meza | - |
dc.creator | REYNALDO RAMIREZ CHACON | - |
dc.creator | Srivatsan Padmanabhan | - |
dc.creator | Hugo Mendieta Zerón | - |
dc.date | 2020-10-07 | - |
dc.date.accessioned | 2022-04-21T06:02:50Z | - |
dc.date.available | 2022-04-21T06:02:50Z | - |
dc.identifier | http://hdl.handle.net/20.500.11799/109286 | - |
dc.identifier.uri | http://ri.uaemex.mx/handle20.500.11799/109286 | - |
dc.description | to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately. | - |
dc.language | eng | - |
dc.publisher | The Journal of Infection in Developing Countries | - |
dc.relation | 14 | - |
dc.relation | 9 | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | - |
dc.source | 2036-6590 | - |
dc.subject | Nitazoxanide | - |
dc.subject | Coronavirus | - |
dc.subject | Pregnancy | - |
dc.subject | Ambulatory | - |
dc.subject | Internal medicine | - |
dc.subject | info:eu-repo/classification/cti/3 | - |
dc.title | Nitazoxanide against COVID-19 in three explorative scenarios | - |
dc.type | article | - |
dc.audience | students | - |
dc.audience | researchers | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
Appears in Collections: | Producción |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.